Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 240-458-0 | CAS number: 16409-44-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Remarks:
- Thirteen-week repeated dose study
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1987
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Justification for type of information:
- This information is used for read-across to Neryl acetate multi
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 987
- Report date:
- 1982
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Specifications for the Conduct of Studies to Evaluate the Toxic and Carcinogenic Potential of Chemical, Biological, and Physical Agents in Laboratory Animals for the National Toxicology Program (NTP)
- Principles of method if other than guideline:
- As a pre-study for a carcinogenicity study, rats (n= 10/sex/dose) were exposed 5 days/week by gavage to geranyl acetate (71% geranyl acetate (CAS 105-87-3) and 29% citronellyl acetate (CAS 150-84-5)) in corn oil at doses of 250, 500, 1,000, 2,000 or 4,000 mg/kg bw/day for 13 weeks. Vehicle controls received corn oil alone. All animals were observed twice daily for signs of clinical signs, morbidity or mortality. Body weights were recorded every week. The mean body weight of each group was calculated by dividing the total weight of all animals in the group by the number of surviving animals in the group. Necropsies were performed on all animals. The following tissues were examined microscopically (controls and high dose group only): tissue masses, abnormal lymph nodes, skin, mandibular lymph nodes, mammary gland, salivary gland, thigh muscle, sciatic nerve, bone marrow, thymus, larynx, trachea, lungs and bronchi, heart, thyroid, parathyroid, esophagus, stomach, duodenum, jejunum, ileum, colon, mesenteric lymph nodes, liver, pancreas, spleen, kidneys, adrenals, urinary bladder, seminal vesicles/ prostate/ testes or ovaries/ uterus, brain, pituitary, and spinal cord. The health of the animals was monitored during the course of the studies according to the protocols of the NTP Sentinel Animal Program.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Geranyl acetate
- EC Number:
- 203-341-5
- EC Name:
- Geranyl acetate
- Cas Number:
- 105-87-3
- Molecular formula:
- C12H20O2
- IUPAC Name:
- (2E)-3,7-dimethylocta-2,6-dien-1-yl acetate
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source of test material: Lot No. 36948 (Givaudan Corp.)
- Purity: ≥ 70.63% (impurities: 29% citronellyl acetate, remaining impurities (7 impurities, not further identified at appr. 0.37%).
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: in the dark at 5°C
- Stability under test conditions: stable (as shown by reanalysis)
- Solubility and stability of the test substance in the solvent/vehicle: Samples of the mixtures selected at random during the carcinogenicity study were analyzed periodically at Southern Research Institute, and the results indicated that all analyzed mixtures were properly formulated (within 10% of the target concentration).
Test animals
- Species:
- rat
- Strain:
- other: F344/N
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Industries, Indianapolis, USA
- Age at study initiation: 5-6 weeks
- Weight at study initiation: 101.3 - 109.8 g (mean weight males per dose group), 86.7 - 95.4 g (mean weight females per dose group)
- Fasting period before study: no
- Housing: group-housed (5 animals/ cage), polycarbonate cages with bedding of Beta Chips@ heat treated hardwood chips, Northeastern Products Corp., Warrensburg, NY, USA
- Diet: ad libitum, Wayne@ Lab Blox pellets, Allied Mills, Inc. Chicago, IL, USA
- Water: ad libitum, tap water
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 16-27
- Humidity (%): 15-96
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 5 mL/kg bw
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Appropriate amounts of geranyl acetate were mixed with enough corn oil to give the desired concentration for the high dose groups. Gavage solutions for lower doses were prepared by diluting this stock solution with corn oil. Geranyl acetate/corn oil mixtures at the 2% (v/v) level were analyzed at Midwest Research Institute and found to be stable at room temperature for 7 days. Samples of the mixtures selected at random were analyzed periodically at Southern Research Institute, and the results indicated that all analyzed mixtures were properly formulated (within 10% of the target concentration). The results from the three analyses conducted at Midwest Research Institute also confirmed this finding.
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 5 days/ week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 250 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 2 000 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 4 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: A single dose test and a fourteen day exposure study were performed. Together with this 13-week exposure study these studies were used as pre-tests for a carcinogenicity study.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Observed twice daily for clinical signs, morbidity, and mortality;
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (all animals, major tissues or organs were examined)
HISTOPATHOLOGY: Yes (control and high dose animals). The following tissues or organs were examined microscopically for control and high dose groups: gross lesions, tissue masses, abnormal lymph nodes, skin, mandibular lymph nodes, mammary gland, salivary gland, thigh muscle, scatic nerve, bone marrow, thymus, larynx, trachea, lungs and bronchi, heart, thyroid, parathyroid, esophagus, stomach, duodenum, jejunum, ileum, colon, mesenteric lymph nodes, liver, pancreas, spleen, kidneys, adrenals, urinary bladder, seinal vesicles/prostate/ testes or ovaries/uterus, brain, pituitary, and spinal cord. - Statistics:
- Probabilities of survival were estimated by the product-limit procedure of Kaplan and Meier (1958). Animals were statistically censored as of the time that they died of other than natural causes or were found to be missing; animals dying from natural causes were not sta- tistically censored. Statistical analyses for a possible dose-related effect on survival used the method of Cox (1972) for testing two groups for equality and Tarone's (1975) extensions of Cox's methods for testing for a dose-related trend. All reported P-values for the survival analyses are two-sided.
The incidence of neoplastic or nonneoplastic lesions has been given as the ratio of the number of animals bearing such lesions at a specific anatomic site to the number of animals in which that site was examined. In most instances, the denominators included only those animals forwhich that site was examined histologically. However, when macroscopic examination was required to detect lesions (e.g., skin or mammary tumors) prior to histologic sampling, or when lesions could have appeared at multiple sites (e.g., lymphomas), the denominators consist of the number of animals on which necropsies were performed.
For the statistical analysis of tumor incidence data, two different methods of adjusting for intercurrent mortality were employed. Each used the classical method for combining contingency tables developed by Mantel and Haenszel (1959). Tests of significance included pairwise comparisons of high and low dose groups with controls and tests for overall dose-response trends.
In addition to these tests, one other set of statistical analyses was carried out and reported in the tables analyzing primary tumors: the Fisher’s exact test for pairwise comparisons and Cochran-Armitage linear trend test for dose- response trends (Armitage, 1971; Gart et al., 1979). These tests were based on the overall proportion of tumor-bearing animals. All reported P values for the tumor incidence analyses are one-sided.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No compound-related clinical signs were observed.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Two of 10 male rats and 1/10 female rats died at 4000 mg/kg bw/day. One male rat in the 500 mg/kg bw/day group dies due to gavage error.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At 4000 mg/kg bw/day mean body weight compared to controls was depressed in males and in females (-19% and -8%, respectively, compared to controls). No significant effect on body weight was found for the other groups (males: -1%, -1%, 0% and -5% for groups dosed at 250, 500, 1000 and 2000 mg/kg bw/day, respectively; females: -1%, -4%, 0% and +1% for groups dosed at 250, 500, 1000 and 2000 mg/kg bw/day, respectively).
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Reddened mucosa of the stomach was observed in 3/10 males that received 4000 mg/kg bw/day.
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test substance-related histopathologic effects were observed.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 2 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- mortality
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
Results of the pre-studies (rat):
Single dose study: All rats receiving 8000 mg/kg bw died on day 2. No further mortality occurred. All rats were inactive immediately after dosing.
Fourteen-day study: All animals survived to the end of the dosing period. Weight gains by dosed and control groups were comparable. The activity of all rats that received 1000 mg/ kg decreased after dosing between days 2 and 4 of the studies. No compound-related effects were observed during necropsy.
Results in mice
Single dose study: Four of the five male mice receiving 8000 mg/kg bw/day died (two on day 2 and two on day 3), and 5/5 female mice that received this dose died (four on day 2 and one on day 3). All mice administered 1000-8000 mg/kg bw were inactive immediately after dosing.
Fourteen-day study: Three female mice that received 2000 mg/kg bw/day died. All other animals survived to the end of the dosing period. Mean body weight gains by dosed groups were not adversely affected by administration of geranyl acetate. All mice that received 1000 mg/kg bw/day or more were inactive after the dose was administered but they returned to normal within 24 hours. One of five male mice that received 2000 mg/kg bw/day had a thickened duodenal wall, and 3/ 5 female mice receiving 2000 mg/kg bw/day had a thickened wall of the cardiac stomach.
Thirteen-week study: Seven of ten males and 9/10 females receiving 2000 mg/kg bw/day died. Three female mice at lower doses died as a result of gavage error. All other animals survived to the end of the studies. Overall, mean body weights of dosed groups were comparable with those of the controls. Cytoplasmic vacuolization of the liver, kidney, and myocardium was observed in male and female mice at the 2000 mg/kg bw/day dose level (liver: 7/10 males and 8/9 females; kidney: 2/10 males and 4/9 females; myocardium: 2/10 males and 1/9 females). The vacuoles were found to contain lipids. In the liver, the lipid droplets varied in size from barely visible to larger than the nuclei of the hepatocytes. The nuclei of the hepatocytes remained in the center of the cells. The lipidosis was present throughout the lobules, particularly in the periportal area. The lipid droplets in the kidney were present in the cytoplasm of the proximal tubules in a subnuclear location. The myocardium contained fine lipid droplets within the fibers and the myofibriles. Stomach lesions, consisting of focal suppurative inflammation, focal ulcerative inflamma tion, or submucosal edema, were found in 2/10 males and 6/10 females that received 2000 mg/kg bw/day.
Since the results in mice were not considered to affect the conclusion based on the rat studies, the results were not further summarized in detail.
Applicant's summary and conclusion
- Conclusions:
- A 13-week repeated dose study was conducted with food grade Geranyl Acetate in rats. Mortality was seen (2/10 males; 1/10 females) and the body weight gain was decreased in the high dose group (dosed at 4000 mg/kg bw/day) in males and females, The NOAEL is 2000 mg/kg bw/d.
- Executive summary:
In a 13-week study with 10 rats/sex/dose, and test doses of 0, 250, 500, 1000, 2000 and 4000 mg/kg bw/day, rats were observed for clinical signs, morbidity, and mortality twice daily; rats were weighed weekly; necropsies were performed on all animals, histological examinations were performed on control and high-dose groups. In this study no test substance-related histopathological effects or increase in tumour-incidence were noted. Since the survival and the body weight gain was decreased in the high dose group (dosed at 4000 mg/kg bw/day) in males and females, the NOAEL of the 13-week study was established to be 2000 mg/kg bw/day.
In parallel the same set of tests (including the two-year carcinogenicity study) were performed with mice. The results in the mice studies were not considered to affect the conclusion based on the rat studies.
Other available information
This 13 wk study was a pre-study for a carcinogenicity study which is shortly presented below as well as an other preliminary study
A carcinogenicity study was conducted in which rats (n= 50/sex/dose) were exposed daily by gavage to Geranyl Acetate in corn oil at doses of 1,000 and 2,000 mg/kg bw/day for two years. Several pre-tests were performed in order to determine the final test concentrations in the carcinogenicity test. These pre-studies were reported to be performed with Geranyl Acetate containing 6-17% Citronellyl Acetate (‘mono’).
In a 14-day study with 5 rats/sex/dose, with test doses of 0, 62, 125, 250, 500 and 1000 mg/kg bw/day, rats were observed for clinical signs, morbidity, and mortality twice daily; rats were weighed weekly; necropsy was performed on all animals. No mortality was seen, weight gains by dosed and control groups were comparable. The activity of all rats that received 1,000 mg/ kg bw/day decreased after dosing between days 2 and 4 of the study. No compound-related effects were observed during necropsy.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.